Holen Sie sich die Stockscreener-App
0.97
4.30%
0.04
Schlusskurs vom Vortag:
$0.93
Offen:
$0.9408
24-Stunden-Volumen:
33,778
Relative Volume:
0.38
Marktkapitalisierung:
$6.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.29M
KGV:
-0.2431
EPS:
-3.99
Netto-Cashflow:
$-12.27M
1W Leistung:
+4.85%
1M Leistung:
-17.09%
6M Leistung:
-40.67%
1J Leistung:
-68.20%
1-Tages-Spanne:
$0.9301
$0.98
1-Wochen-Bereich:
$0.9055
$0.98
52-Wochen-Spanne:
$0.90
$5.00
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Vergleichen Sie APRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.97 | 5.87M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.44 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.64 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
409.47 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
853.97 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.47 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
Why Aprea Therapeutics Inc. stock could rally in 20252025 Big Picture & Low Drawdown Investment Ideas - Улправда
Can Aprea Therapeutics Inc. stock weather global recession2025 Top Gainers & Weekly Breakout Watchlists - Улправда
Aprea Therapeutics (NASDAQ:APRE) Given New $5.00 Price Target at HC Wainwright - Defense World
Why retail investors favor Aprea Therapeutics Inc. stockTrade Volume Report & Free Reliable Trade Execution Plans - DonanımHaber
Aprea Therapeutics reports progress in cancer drug development By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains Aprea Therapeutics (APRE) Buy Recommendation - Nasdaq
Aprea Therapeutics (APRE): HC Wainwright Maintains 'Buy' Rating, Lowers Price Target | APRE Stock News - GuruFocus
Aprea Therapeutics CEO issues letter to shareholders highlighting outlook for 2026 - marketscreener.com
Aprea Therapeutics reports progress in cancer drug development - Investing.com India
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 - The Manila Times
Aprea Therapeutics Highlights Clinical Progress and Strategic Plans in Shareholder Update Letter - Quiver Quantitative
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - MSN
Insider Buying: John Hamill Acquires Additional Shares of Aprea Therapeutics Inc (APRE) - GuruFocus
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Duey Marc buys $25,000 in shares By Investing.com - Investing.com Canada
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock - Investing.com India
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock By Investing.com - Investing.com South Africa
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock - Investing.com
Aprea Therapeutics Director Marc Duey Acquires 21,459 Shares - TradingView — Track All Markets
Dir Duey Buys 21,459 ($25K) Of Aprea Therapeutics Inc [APRE] - TradingView — Track All Markets
Aprea Therapeutics raises $3.1 million in private placement By Investing.com - Investing.com India
Aprea Therapeutics, Inc. announced that it expects to receive $3.055822 million in funding - marketscreener.com
Aprea Therapeutics raises $3.1 million in private placement - Investing.com
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Aprea Therapeutics (Nasdaq: APRE) prices $3.1M private placement to extend cash runway into Q1 2027 - Stock Titan
Aprea Therapeutics (NASDAQ: APRE) registers 219,242 shares under 2019 equity plan - Stock Titan
Aprea Therapeutics secures $3.1M in private placement - MSN
Why Aprea Therapeutics Inc. stock is seen as undervaluedMarket Weekly Review & Growth Focused Investment Plans - Newser
Aprea Therapeutics, Inc. (NASDAQ:APRE): Is Breakeven Near? - simplywall.st
How Aprea Therapeutics Inc. stock performs in rising dollar environmentJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - Newser
Head and Neck Cancer Therapeutics Market | Global Market Analysis Report2035 - Fact.MR
Is Aprea Therapeutics Inc a good long term investmentRSI Overbought/Oversold & Learn From the Strategies of Institutions - earlytimes.in
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen - MSN
Why Aprea Therapeutics Inc. stock could outperform in 2025July 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Aprea Therapeutics Inc. stock sustain free cash flow growthWatch List & Weekly Momentum Picks - newser.com
How supply chain issues affect Aprea Therapeutics Inc. stockEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
Is Aprea Therapeutics Inc. stock a top momentum play2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
Tools to assess Aprea Therapeutics Inc.’s risk profileQuarterly Earnings Summary & Fast Exit and Entry Strategy Plans - newser.com
Will Aprea Therapeutics Inc. stock outperform value stocks2025 Valuation Update & Weekly High Return Opportunities - newser.com
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
2.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):